Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687562 | 0.84 | POLB (0.30) | — | |
| SCHEMBL27822475 | 0.82 | SMN1; SMN2 (0.36) | MAPTATML3MBTL1TSHR | |
| SCHEMBL6333649 | 0.82 | DDB1 (0.38) | KDM4EMAPT | |
| SCHEMBL13389814 | 0.82 | KDM4E (0.36) | KDM4EMAPTATML3MBTL1OPRM1 | |
| SCHEMBL20400106 | 0.77 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL21465773 | 0.75 | CYP2D6 (0.46) | KDM4EL3MBTL1OPRM1OPRD1OPRK1 | |
| SCHEMBL10393923 | 0.71 | BLM (0.43) | OPRM1OPRD1OPRK1 | |
| SCHEMBL4811675 | 0.71 | MAPT (0.41) | KDM4EMAPTATML3MBTL1OPRM1 | |
| SCHEMBL18586888 | 0.71 | ALOX15 (0.38) | ATML3MBTL1OPRM1OPRD1OPRK1 | |
| SCHEMBL2350223 | 0.70 | ADORA1 (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571198-B1 | BICYCLIC AMINES AS JAK KINASE INHIBITORS | LEO PHARMA AS (DK) | 2023-02-01 | — | — | EP | disclosed |
| US-10851116-B2 | Bicyclic amines as novel JAK kinase inhibitors | LEO PHARMA A/S (DK) | 2020-12-01 | — | — | US | disclosed |
| WO-2018134352-A1 | BICYCLIC AMINES AS NOVEL JAK KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851116-B2 | Bicyclic amines as novel JAK kinase inhibitors | JAK1, JAK2, JAK3 | KDM4E 984/4885MAPT 3818/4885ATM 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.